Heartflow (NASDAQ:HTFL) Stock Price Up 10% Following Analyst Upgrade

Heartflow, Inc. (NASDAQ:HTFL)’s stock price rose 10% during mid-day trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $35.00 to $39.00. Canaccord Genuity Group currently has a buy rating on the stock. Heartflow traded as high as $34.60 and last traded at $34.58. Approximately 161,873 shares traded hands during trading, a decline of 68% from the average daily volume of 501,088 shares. The stock had previously closed at $31.43.

HTFL has been the subject of several other research reports. JPMorgan Chase & Co. initiated coverage on Heartflow in a research note on Tuesday, September 2nd. They set an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen raised Heartflow to a “hold” rating in a research note on Saturday, August 16th. Stifel Nicolaus initiated coverage on Heartflow in a research note on Tuesday, September 2nd. They set a “buy” rating and a $35.00 price objective for the company. Zacks Research raised Heartflow to a “hold” rating in a research note on Wednesday, September 3rd. Finally, Morgan Stanley initiated coverage on Heartflow in a research note on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 price objective for the company. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $36.60.

Heartflow Price Performance

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million during the quarter, compared to analysts’ expectations of $43.20 million.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.